Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a strategic refocusing of its research and development portfolio following the expiration and termination of its option and license arrangements with PinCell S.r.l. for the asset PC111 on August 31. The decision, which was not driven by any new negative scientific finding regarding PC111, allows the company to concentrate its R&D resources on its NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business. This move underscores the company's commitment to optimizing its pipeline and capitalizing on its dual revenue streams.
Scinai is advancing two IL-17 programs within its NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. This potential grant could significantly offset development costs and accelerate the program's progress. The NanoAb platform, which leverages single-domain antibodies, is a key focus for the company, offering potential advantages in formulation and delivery compared to conventional antibodies.
In addition to its R&D efforts, Scinai's CDMO business, Scinai Biopharma Services Ltd., has reported approximately $3.1 million in committed customer orders as of August 16. The company continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities. The CDMO segment provides a steady revenue stream to support the company's operations and reduce reliance on external financing.
This strategic pivot comes at a time when many biotech firms are reassessing their portfolios to extend cash runways and focus on high-probability assets. By terminating the PC111 arrangement, Scinai avoids potential future milestone payments and royalties, freeing up resources for its core programs. The decision also aligns with the company's goal of achieving near-term value drivers, such as the intradermal psoriasis program and the growth of its CDMO services.
Investors will be watching how Scinai executes on these priorities. The company's ability to secure the Polish grant and convert its CDMO pipeline into revenue will be critical for its financial health and stock performance. With a refocused strategy, Scinai aims to leverage its scientific expertise and manufacturing capabilities to create sustainable value for shareholders.
For more information, visit the full press release at https://ibn.fm/nnx0Z.
